Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · IEX Real-Time Price · USD
11.32
+0.13 (1.16%)
Jul 22, 2024, 10:10 AM EDT - Market open
Lexeo Therapeutics Employees
Lexeo Therapeutics had 58 employees as of December 31, 2023. The number of employees increased by 34 or 141.67% compared to the previous year.
Employees
58
Change
34
Growth
141.67%
Revenue / Employee
n/a
Profits / Employee
-$1,196,862
Market Cap
380.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 58 | 34 | 141.67% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Organogenesis Holdings | 862 |
| Revance Therapeutics | 597 |
| uniQure | 480 |
| Talkspace | 472 |
| Xeris Biopharma Holdings | 377 |
| Sight Sciences | 214 |
| Vanda Pharmaceuticals | 203 |
| TScan Therapeutics | 154 |
LXEO News
- 6 days ago - Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet - Benzinga
- 7 days ago - Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - GlobeNewsWire
- 14 days ago - Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - GlobeNewsWire
- 3 months ago - Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy - GlobeNewsWire
- 4 months ago - Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing - GlobeNewsWire